Currently, there are two indications for receiving the drug: 5q SMA due to biallelic SMN1-gene mutation and clinical diagnosis of SMA type 1, or 5q SMA due to biallelic SMN1-gene mutation and a maximum of four copies of SMN2-genes in patients less than two years of age. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.